SLC7A2 and prostate cancer: MDSCs in prostate cancer tissues can upregulate cationic amino acid transporter 2 (CAT2), ARG‐1, and nitric oxide synthase 2 (NOS2) expression, decreasing l‐arginine production, increasing nitric oxide (NO) production, and enhancing the detrimental effects on T cells.49